Document is current
Any future updates will be listed below
-
Authors
Van Oekelen, Oliver https://orcid.org/0000-0002-5824-197X
Aleman, Adolfo https://orcid.org/0000-0002-8884-2100
Upadhyaya, Bhaskar
Schnakenberg, Sandra
Madduri, Deepu
Gavane, Somali
Teruya-Feldstein, Julie
Crary, John F.
Fowkes, Mary E. https://orcid.org/0000-0003-2699-5555
Stacy, Charles B.
Kim-Schulze, Seunghee
Rahman, Adeeb
Laganà , Alessandro
Brody, Joshua D. https://orcid.org/0000-0002-0850-6730
Merad, Miriam https://orcid.org/0000-0002-4481-7827
Jagannath, Sundar https://orcid.org/0000-0003-2934-6518
Parekh, Samir https://orcid.org/0000-0001-9694-8469
-
Funding
Funding for this research was provided by:
Amgen
Bristol-Myers Squibb
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA244899, CA244899, R01 CA246239-01)
Karyopharm Therapeutics
George Mason University
Bill and Melinda Gates Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19 AI128949, U19 AI118610)
- License Information
-
More Information
Article History
Received: 6 May 2021
Accepted: 28 September 2021
First Online: 10 December 2021
Competing interests
: O.V.O. has no relevant conflicts to disclose. A.A. has no relevant conflicts to disclose. B.U. has no relevant conflicts to disclose. S.S. has no relevant conflicts to disclose. S.S. is currently employed by Sema4 but was not working for the company at the time of preparation of the manuscript. D.M. has worked as a consultant for Bristol Myers Squibb, Celgene, Foundation Medicine, GSK, Janssen, Kinevant and Sanofi and has received grant and research support from Allogene, Amgen, Bristol Myers Squibb, Celgene, Janssen and Regeneron. D.M. is currently employed by Johnson & Johnson but was not working for the company at the time of preparation of the manuscript. S.G. has no relevant conflicts to disclose. J.T.F. has no relevant conflicts to disclose. J.F.C. has no relevant conflicts to disclose. C.B.S. is a member of the ciltacabtagene autoleucel Risk Evaluation and Mitigation Strategy advisory board. S.K.S. has no relevant conflicts to disclose. A.R. is currently employed by Immunai but was not working for the company at the time of preparation of the manuscript. A.L. has no relevant conflicts to disclose. J.D.B. has received consulting fees from Celldex, Genentech, Gilead, Janssen, Kite and Merck and has received research funding or reagents provided by Celldex, Genentech, Janssen, Kite and Merck. M.M. has no relevant conflicts to disclose. S.J. has received consulting fees from Bristol Myers Squibb, Janssen, Karyopharm, Merck, Sanofi and Takeda. S.P. receives research funding from Amgen, Celgene/Bristol Myers Squibb and Karyopharm and consulting fees from Foundation Medicine. All other authors declare no competing interests.
